An international commission of global experts convened by the International AIDS Society and The Lancet in 2018 advised that to eliminate HIV, global treatment efforts should be complemented by a robust scale-up in primary HIV prevention, including the development of a preventive vaccine. To date, only one HIV vaccine trial has shown moderate efficacy of the vaccine. This trial done in Thailand used an ALVAC-HIV prime, followed by two boosts of ALVAC-HIV plus AIDSVAX B/E Alum adjuvanted protein. A follow-up trial (HVTN 702) done in South Africa that used an adapted HIV subtype C vaccine adjuvanted with MF-59 was recently discontinued in February, 2020, because of lack of efficacy, highlighting the need for novel vaccine approaches.

中文翻译：

---

缩短艾滋病毒疫苗接种方案以实现高覆盖率。

由国际艾滋病协会和《柳叶刀》杂志于2018年召集的一个由全球专家组成的国际委员会建议，为消除艾滋病毒，应对全球治疗的努力应辅之以在初级艾滋病毒预防方面的强有力的扩大，包括开发预防性疫苗。迄今为止，只有一项HIV疫苗试验显示了该疫苗的中等效力。在泰国进行的这项试验使用了ALVAC-HIV初免，然后两次使用ALVAC-HIV加AIDSVAX B / E明矾佐剂蛋白。由于缺乏疗效，南非在2020年2月终止了在南非进行的随访试验（HVTN 702），该试验使用了经改良的HIV亚型MF-59佐剂的HIV辅助疫苗，由于缺乏疗效，强调了对新型疫苗方法的需求。